Literature DB >> 20840333

Cephalosporin and fluoroquinolone combinations are highly associated with CTX-M β-lactamase-producing Escherichia coli: a case-control study in a French teaching hospital.

P Cassier1, S Lallechère, S Aho, K Astruc, C Neuwirth, L Piroth, P Chavanet.   

Abstract

The aim of this study was to investigate the risk factors associated with CTX-M-producing Escherichia coli strains isolated from infected or colonized patients. From 191 clinical samples, a case-control study was designed. From January 2005 to December 2007, 98 hospitalized patients infected or colonized with CTX-M-producing E. coli were included in the study. They were matched 1 : 1 with controls that had a non-CTX-M-producing E. coli infection on the basis of the site of sample, the unit of hospitalization and the time at risk. The rate of CTX-M-producing E. coli among those producing extended spectrum β-lactamases was always ≥90% from 2005 to 2008. All strains were susceptible to carbapenems. However, we observed a high rate of co-resistance to ciprofloxacin (61%), sulphonamides (86%) and gentamicin (34%). Significant risk factors identified by multivariate analysis were recurrent infections (OR = 2.93), presence of artificial nutrition (OR = 3.99), and recent exposure to quinolones (OR = 4.39), third- or fourth-generation cephalosporin (OR = 3.49) and the combination of both antibiotic classes (OR = 5.50). This report highlights the dramatic increase of CTX-M-producing E. coli and the need for changes in the use of antimicrobial drugs and in infection control measures to manage this major health concern.
© 2011 The Authors. Clinical Microbiology and Infection © 2011 European Society of Clinical Microbiology and Infectious Diseases.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 20840333     DOI: 10.1111/j.1469-0691.2010.03349.x

Source DB:  PubMed          Journal:  Clin Microbiol Infect        ISSN: 1198-743X            Impact factor:   8.067


  20 in total

Review 1.  Individualising Therapy to Minimize Bacterial Multidrug Resistance.

Authors:  A J Heffernan; F B Sime; J Lipman; J A Roberts
Journal:  Drugs       Date:  2018-04       Impact factor: 9.546

2.  Risk factors for infection or colonization with CTX-M extended-spectrum-β-lactamase-positive Escherichia coli.

Authors:  Jennifer H Han; Kei Kasahara; Paul H Edelstein; Warren B Bilker; Ebbing Lautenbach
Journal:  Antimicrob Agents Chemother       Date:  2012-08-13       Impact factor: 5.191

3.  Quinolone-resistant Escherichia coli O127a:K63 serotype with an extended-spectrum-beta-lactamase phenotype from a food poisoning outbreak in China.

Authors:  Rongzhang Hao; Shaofu Qiu; Yong Wang; Guang Yang; Wenli Su; Lixue Song; Jia Zhang; Jiaxu Chen; Leili Jia; Ligui Wang; Hongbin Song
Journal:  J Clin Microbiol       Date:  2012-05-02       Impact factor: 5.948

Review 4.  [Community acquired urinary tract infections - association with risk factors : Changes in causative organisms and resistance over time].

Authors:  B Ubrig; M Böhme; A Merklinghaus; F Wagenlehner
Journal:  Urologe A       Date:  2017-06       Impact factor: 0.639

5.  The Path of More Resistance: a Comparison of National Healthcare Safety Network and Clinical Laboratory Standards Institute Criteria in Developing Cumulative Antimicrobial Susceptibility Test Reports and Institutional Antibiograms.

Authors:  Alexander Viloria Winnett; Vinay Srinivasan; Matthew Davis; Tara Vijayan; Daniel Z Uslan; Omai B Garner; Annabelle de St Maurice
Journal:  J Clin Microbiol       Date:  2021-12-01       Impact factor: 11.677

6.  [Prevalence and risk factors for extended-spectrum β-lactamase-producing Escherichia coli causing community-onset urinary tract infections in Colombia].

Authors:  Victor M Blanco; Juan J Maya; Adriana Correa; Marcela Perenguez; Juan S Muñoz; Gabriel Motoa; Christian J Pallares; Fernando Rosso; Lorena Matta; Yamile Celis; Martha Garzon; María V Villegas
Journal:  Enferm Infecc Microbiol Clin       Date:  2016-01-13       Impact factor: 1.731

7.  Epidemiology and risk factors for isolation of Escherichia coli producing CTX-M-type extended-spectrum β-lactamase in a large U.S. Medical Center.

Authors:  Kayoko Hayakawa; Sureka Gattu; Dror Marchaim; Ashish Bhargava; Mohan Palla; Khaled Alshabani; Uma Mahesh Gudur; Harish Pulluru; Pradeep Bathina; Pranathi Rao Sundaragiri; Moumita Sarkar; Hari Kakarlapudi; Balaji Ramasamy; Priyanka Nanjireddy; Shah Mohin; Meenakshi Dasagi; Satya Datla; Vamsi Kuchipudi; Swetha Reddy; Shobha Shahani; Vijaya Upputuri; Satya Marrey; Vedavyas Gannamani; Nandhini Madhanagopal; Srinadh Annangi; Busani Sudha; Kalyan Srinivas Muppavarapu; Judy A Moshos; Paul R Lephart; Jason M Pogue; Karen Bush; Keith S Kaye
Journal:  Antimicrob Agents Chemother       Date:  2013-06-10       Impact factor: 5.191

8.  Risk factors for community-acquired urinary tract infections caused by ESBL-producing enterobacteriaceae--a case-control study in a low prevalence country.

Authors:  Arne Søraas; Arnfinn Sundsfjord; Irene Sandven; Cathrine Brunborg; Pål A Jenum
Journal:  PLoS One       Date:  2013-07-23       Impact factor: 3.240

9.  An Audit-Based, Infectious Disease Specialist-Guided Antimicrobial Stewardship Program Profoundly Reduced Antibiotic Use Without Negatively Affecting Patient Outcomes.

Authors:  Hannah Nilholm; Linnea Holmstrand; Jonas Ahl; Fredrik Månsson; Inga Odenholt; Johan Tham; Eva Melander; Fredrik Resman
Journal:  Open Forum Infect Dis       Date:  2015-03-23       Impact factor: 3.835

10.  A multidisciplinary intervention to reduce infections of ESBL- and AmpC-producing, gram-negative bacteria at a University Hospital.

Authors:  Jenny Dahl Knudsen; Stig Ejdrup Andersen
Journal:  PLoS One       Date:  2014-01-23       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.